Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects

The presence of somatostatin receptors (SSTRs) is crucial in planning the therapy of patients with neuroendocrine tumors. This applies especially to patients in whom surgery has proven unsuccessful or there are contraindications for it. Increased SSTR expression has been observed in many cancers ori...

Full description

Bibliographic Details
Main Authors: Beata Polowczyk, Marcin Kałużny, Marek Bolanowski
Format: Article
Language:English
Published: Index Copernicus International S.A. 2020-07-01
Series:Postępy Higieny i Medycyny Doświadczalnej
Subjects:
Online Access:http://phmd.pl/gicid/01.3001.0014.3056
id doaj-15f63eaa6bfd4da394adfdfdffc55bef
record_format Article
spelling doaj-15f63eaa6bfd4da394adfdfdffc55bef2020-11-25T03:38:28ZengIndex Copernicus International S.A.Postępy Higieny i Medycyny Doświadczalnej0032-54491732-26932020-07-017427228210.5604/01.3001.0014.305601.3001.0014.3056Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effectsBeata Polowczyk0Marcin Kałużny1Marek Bolanowski2Katedra i Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Uniwersytet Medyczny im. Piastów Śląskich we WrocławiuKatedra i Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Uniwersytet Medyczny im. Piastów Śląskich we WrocławiuKatedra i Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Uniwersytet Medyczny im. Piastów Śląskich we WrocławiuThe presence of somatostatin receptors (SSTRs) is crucial in planning the therapy of patients with neuroendocrine tumors. This applies especially to patients in whom surgery has proven unsuccessful or there are contraindications for it. Increased SSTR expression has been observed in many cancers originating in the neuroendocrine system. Among them we distinguish anterior pituitary adenomas producing GH in excess and leading to the development of acromegaly, adenocorticotropic adenomas that autonomously synthesize ACTH, which leads to the development of ACTH-dependent Cushing’s syndrome (Cushing’s disease), as well as adenomas of the anterior pituitary from thyrotropic cells. Rich expression of these receptors has been confirmed in epithelial tumors of neuroendocrine origin in the gastrointestinal tract, pancreas and lungs. Somatostatin analogues, also called somatostatin receptor ligands, are effective in symptomatic therapy; they enable disease control, exhibit anti-proliferative effects and allow hormonal balance, which reduces mortality among patients and improves their quality of life. The antitumor effect of somatostatin analogues has been proven in in vitro and in vivo studies. In therapy they are usually well tolerated and safe. For many years, somatostatin analogues have maintained an important place in the treatment of neuroendocrine tumors and are still the subject of many studies. The aim of the study is to analyze, based on available literature, therapeutic indications for the use of somatostatin analogues, taking into account contraindications for therapy and its possible side effects. http://phmd.pl/gicid/01.3001.0014.3056somatostatin analoguespituitary adenomasneuroendocrine tumors
collection DOAJ
language English
format Article
sources DOAJ
author Beata Polowczyk
Marcin Kałużny
Marek Bolanowski
spellingShingle Beata Polowczyk
Marcin Kałużny
Marek Bolanowski
Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
Postępy Higieny i Medycyny Doświadczalnej
somatostatin analogues
pituitary adenomas
neuroendocrine tumors
author_facet Beata Polowczyk
Marcin Kałużny
Marek Bolanowski
author_sort Beata Polowczyk
title Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
title_short Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
title_full Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
title_fullStr Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
title_full_unstemmed Somatostatin analogues in the therapy of neuroendocrine tumors: Indications, contraindications, side-effects
title_sort somatostatin analogues in the therapy of neuroendocrine tumors: indications, contraindications, side-effects
publisher Index Copernicus International S.A.
series Postępy Higieny i Medycyny Doświadczalnej
issn 0032-5449
1732-2693
publishDate 2020-07-01
description The presence of somatostatin receptors (SSTRs) is crucial in planning the therapy of patients with neuroendocrine tumors. This applies especially to patients in whom surgery has proven unsuccessful or there are contraindications for it. Increased SSTR expression has been observed in many cancers originating in the neuroendocrine system. Among them we distinguish anterior pituitary adenomas producing GH in excess and leading to the development of acromegaly, adenocorticotropic adenomas that autonomously synthesize ACTH, which leads to the development of ACTH-dependent Cushing’s syndrome (Cushing’s disease), as well as adenomas of the anterior pituitary from thyrotropic cells. Rich expression of these receptors has been confirmed in epithelial tumors of neuroendocrine origin in the gastrointestinal tract, pancreas and lungs. Somatostatin analogues, also called somatostatin receptor ligands, are effective in symptomatic therapy; they enable disease control, exhibit anti-proliferative effects and allow hormonal balance, which reduces mortality among patients and improves their quality of life. The antitumor effect of somatostatin analogues has been proven in in vitro and in vivo studies. In therapy they are usually well tolerated and safe. For many years, somatostatin analogues have maintained an important place in the treatment of neuroendocrine tumors and are still the subject of many studies. The aim of the study is to analyze, based on available literature, therapeutic indications for the use of somatostatin analogues, taking into account contraindications for therapy and its possible side effects.
topic somatostatin analogues
pituitary adenomas
neuroendocrine tumors
url http://phmd.pl/gicid/01.3001.0014.3056
work_keys_str_mv AT beatapolowczyk somatostatinanaloguesinthetherapyofneuroendocrinetumorsindicationscontraindicationssideeffects
AT marcinkałuzny somatostatinanaloguesinthetherapyofneuroendocrinetumorsindicationscontraindicationssideeffects
AT marekbolanowski somatostatinanaloguesinthetherapyofneuroendocrinetumorsindicationscontraindicationssideeffects
_version_ 1724542164005814272